Fig. 3From: Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countriesMeasures of healthcare resource utilization in 5–2-1-positive patients compared with 5–2-1-negative patients. *p < 0.0001. 5–2-1, taking ≥5 doses of oral levodopa/day, OR having ≥2 h ‘off’-time/waking day, OR having ≥1 h troublesome dyskinesia/waking dayBack to article page